

RECEIVED

DEC 02 2002

TECH CENTER 1600/2900

Attorney's Docket No.: 2139-11US – CC/lcl

Montréal, Canada
November 26, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yasuo KONISHI et al.

Serial No.: 09/529,232

Group Art Unit: 1655

Filed: April 10, 2000

Examiner: Janelle TAYLOR

For: TRIVALENT THROMBIN INHIBITOR

Agent: Christian Cawthorn

Direct Line: (514) 847-5256

RECEIVED
TECH CENTER 1600/2900
02 NOV 27 AM 11:33

AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

DEC 05 2002

TECH CENTER 1600/2900

Sir:

In response to the Office Letter dated November 6, 2002 in connection with the above-identified patent application, please amend the application as follows:

IN THE DISCLOSURE

Please insert new pages 1/6 to 6/6 of the Sequence Listing at the end of the specification.

REMARKS

Claims 1 to 14 are now in the application.

Requirements of 37C.F.R. § 1.821 and § 1.825

Enclosed herewith is a Sequence Listing in paper copy and in computer readable copy, along with a Statement.


Assistant Commissioner for Patents

The Sequence Listing has been amended to fully identify the use of Xaa's as required in the Office Action. No new matter has been added. Thus, the disclosure is now believed to comply with the requirements of 37 C.F.R. § 1.821 and § 1.825.

It is submitted, therefore that the claims are in condition for allowance. Reconsideration of the rejections is requested. Allowance of all claims at an early date is solicited.

Respectfully submitted,

26 Nov. 2002
Date

By: 
Christian Cawthorn, Reg. 47,352
Agent for Applicants

SWABEY OGILVY RENAULT
1981 McGill College
Suite 1600
Montréal (Québec)
Canada, H3A 2Y3
(514) 847-4256